Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orion: Brexpiprazole Safety in MDD
NCT01360866Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2011
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Oct 2011; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01360866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01360866.